Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,467Revenue $M1,551Net Margin (%)23.3Z-Score31.5
Enterprise Value $M35,842EPS $1.3Operating Margin %38.7F-Score8
P/E(ttm))78.6Cash Flow Per Share $0.8Pre-tax Margin (%)38.8Higher ROA y-yY
Price/Book12.010-y EBITDA Growth Rate %0Quick Ratio4.8Cash flow > EarningsY
Price/Sales18.45-y EBITDA Growth Rate %52.4Current Ratio5.1Lower Leverage y-yY
Price/Cash Flow115y-y EBITDA Growth Rate %59.3ROA % (ttm)14.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)18.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M198ROI % (ttm)16.0Gross Margin Increase y-yY

Gurus Latest Trades with ALXN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALXNAndreas Halvorsen 2014-09-30 Add0.13%$155.06 - $173.08
($164.22)
$ 188.9615%Add 9.59%2,198,451
ALXNRon Baron 2014-09-30 Add$155.06 - $173.08
($164.22)
$ 188.9615%Add 27.56%12,941
ALXNJoel Greenblatt 2014-09-30 Reduce-0.03%$155.06 - $173.08
($164.22)
$ 188.9615%Reduce -89.45%1,804
ALXNRay Dalio 2014-09-30 Sold Out -0.03%$155.06 - $173.08
($164.22)
$ 188.9615%Sold Out0
ALXNAndreas Halvorsen 2014-06-30 Add0.12%$139.61 - $170.2
($157.93)
$ 188.9620%Add 9.23%2,006,092
ALXNJoel Greenblatt 2014-06-30 Add0.02%$139.61 - $170.2
($157.93)
$ 188.9620%Add 240.11%17,094
ALXNRay Dalio 2014-06-30 Reduce-0.03%$139.61 - $170.2
($157.93)
$ 188.9620%Reduce -47.72%26,332
ALXNJohn Burbank 2014-06-30 Sold Out -0.01%$139.61 - $170.2
($157.93)
$ 188.9620%Sold Out0
ALXNRay Dalio 2014-03-31 Buy 0.06%$129.82 - $183.89
($158.27)
$ 188.9619%New holding, 50371 sh.50,371
ALXNJoel Greenblatt 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 188.9619%New holding, 5026 sh.5,026
ALXNRon Baron 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 188.9619%New holding, 10218 sh.10,218
ALXNJohn Burbank 2014-03-31 Buy 0.01%$129.82 - $183.89
($158.27)
$ 188.9619%New holding, 1318 sh.1,318
ALXNFrank Sands 2014-03-31 Reduce-0.74%$129.82 - $183.89
($158.27)
$ 188.9619%Reduce -28.52%5,268,418
ALXNAndreas Halvorsen 2014-03-31 Reduce-0.65%$129.82 - $183.89
($158.27)
$ 188.9619%Reduce -36.16%1,836,658
ALXNAndreas Halvorsen 2013-12-31 Reduce-0.37%$105.48 - $132.91
($119.84)
$ 188.9658%Reduce -16.72%2,877,008
ALXNAndreas Halvorsen 2013-09-30 Reduce-1.06%$94.34 - $117.28
($109.83)
$ 188.9672%Reduce -37.7%3,454,640
ALXNFrank Sands 2013-09-30 Reduce-0.27%$94.34 - $117.28
($109.83)
$ 188.9672%Reduce -10.5%7,540,405
ALXNAndreas Halvorsen 2013-06-30 Reduce-2.15%$87.99 - $107.86
($96.37)
$ 188.9696%Reduce -41.4%5,544,949
ALXNAndreas Halvorsen 2013-03-31 Add2.99%$83.39 - $102.57
($93.13)
$ 188.96103%Add 135.72%9,462,442
ALXNFrank Sands 2013-03-31 Add0.11%$83.39 - $102.57
($93.13)
$ 188.96103%Add 4.23%8,420,336
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALXN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALXN Ron Baron 2014-09-3012,9410.010.01+27.56%
ALXN Andreas Halvorsen 2014-09-302,198,4511.111.5+9.59%
ALXN Frank Sands 2014-09-305,311,4882.682.2+0.6%
ALXN Joel Greenblatt 2014-09-301,80400-89.45%
ALXN Ray Dalio 2014-09-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALXN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Brennan David RDirector 2014-12-15Buy500$186.99-4.95view
Moriarty John BEVP & General Counsel 2014-12-11Sell3,570$195.53-9.1view
Veneman Ann MDirector 2014-12-11Sell1,235$193.03-7.93view
BELL LEONARDCEO 2014-12-09Sell133,320$198.26-10.36view
Carmichael ClareSVP, Chief HR Officer 2014-12-04Sell10,000$196.25-9.44view
KELLER WILLIAM RDirector 2014-12-04Sell5,000$196.25-9.44view
Sinha VikasEVP & CFO 2014-12-03Sell75,000$198.96-10.67view
BELL LEONARDCEO 2014-11-20Sell5,210$191.96-7.41view
PARVEN ALVIN SDirector 2014-11-11Sell15,000$195.66-9.16view
Sinha VikasEVP & CFO 2014-11-06Sell5,693$195-8.86view

Press Releases about ALXN :

Quarterly/Annual Reports about ALXN:

News about ALXN:

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014 
Weekly Insider Sells Highlight: ORCL, ALXN, WAT, XRAY Dec 08 2014 
CEO of Alexion Pharmaceuticals Sells Company Stock Sep 29 2014 
Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Aug 14 2014 
Weekly CFO Sells Highlight: Facebook Inc., Cardinal Health Inc., Alexion Pharmaceuticals Inc., Therm Feb 10 2014 
Weekly Insider Sells Highlight: EA, ALXN, AAL, TMO Feb 09 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Six High-Impact Sells - Viking Global Investors Aug 26 2013 
CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares Aug 19 2013 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 


More From Other Websites
ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 15 2014
Alexion Announces $500 Million Share Repurchase Program Dec 15 2014
Alexion Announces $500 Million Share Repurchase Program Dec 15 2014
6:30 am Alexion Pharma announced that its Board has authorized a new share repurchase program of up... Dec 15 2014
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with... Dec 10 2014
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with... Dec 10 2014
New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore... Dec 08 2014
Two Gauges That Point To Fund Buying In A Stock Dec 08 2014
Weekly CFO Sells Highlight: Alexion Pharmaceuticals Inc, Equity Residential, Tableau Software Inc. Dec 08 2014
Inside The IBD 50: Challenging Time For Growth Stocks Dec 05 2014
3 Growth Stocks In Buy Range After Recent Breakouts Dec 03 2014
Biotech Stock Roundup: Avanir to be Acquired by Japanese Firm, Biogen Scores in Alzheimer's Study Dec 03 2014
Stock Market News for December 03, 2014 Dec 03 2014
Meet 5 Big Caps Whose Earnings Are Expected To Surge Dec 03 2014
Stock Market Today: Dow Hits High As Stocks Recover Dec 02 2014
The Debate Over The Cost To Develop A New Drug Dec 02 2014
Some Big Cap 20 Names Holding Up In Monday's Sell-Off Dec 01 2014
Valeant's Onexton Gel Gets FDA Approval for Acne Dec 01 2014
Newly Profitable Medivation Riding High On Drug Sales Nov 28 2014
Alexion's Soliris Gets Final Positive NICE Recommendation Nov 28 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK